Background

Septa Therapeutics' technology is designed to block the inflammation characteristic of Alzheimer's Disease (AD). Our approach is entirely new. However, it is based on 20 years of academic research in chronic infrection in the Central Nervous System (CNS) and 5 years of meningitis-related research.

The early research has been completed and is summarized in three issued patents (see Technology).

We are currently in the enviable position to quickly capitalize on this early work to develop a new drug candidate for the treatment of AD.

Pre-clinical trial in progress

Pre-clinical trials have been initiated with Toni Ahtoniemi, Ph.D., at the Boston-based Charles River Discovery Research Services Finland, Ltd.

Initial penetration studies have provided a successful method for administration of the drug-candidate past the BBB into the brain.

We are now preparing a Proof of Mechanism (POM) study, using multiple doses, to establish target engagement, before beginning Proof of Concept experiments.

The POM work will begin in January 2024.